Bionano Genomics reported a 24% year-over-year revenue decline for Q4 2024, totaling $8.2 million, alongside a modest full-year product revenue increase. The company's stock saw a 3.79% decline, closing at $2.9, with an aftermarket increase of 16.49% to $3.25. According to InvestingPro data, the stock has declined over 95% in the past year and is trading near its 52-week low, with an RSI suggesting oversold territory. Despite these fluctuations, Bionano extended its cash runway into Q1 2026 and improved its non-GAAP gross margin significantly.